P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval Article Swipe
Wannee Kantasiripitak
,
An Outtier
,
Debby Thomas
,
João Sabino
,
Séverine Vermeire
,
Maria Rosaria Ferrante
,
Erwin Dreesen
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0831
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0831
Background Extending the infliximab infusion interval has been attempted in patients with Crohn’s disease (CD) and ulcerative colitis (UC) who sustained treatment response following an earlier interval shortening. We aimed to identify predictors of sustained remission after infliximab interval extension. Methods: Data from 30 adult patients (17 CD, 13 UC), who underwent infliximab interval extension following earlier interval shortening, were collected from a single-centre database search. All patients were in steroid-free clinical (two-item patient-reported outcome [PRO2] ≤1 [UC] and ≤8 [CD]) and biological (C-reactive protein [CRP] <5 mg/L or faecal calprotectin [FC] <250 mg/kg) remission at interval extension. Time-to-relapse was modelled using a time-to-event (TTE) model with loss of steroid-free clinical and biological remission being the event of interest (NONMEM7.5). Various hazard functions were explored, and disease type, time-varying infliximab concentrations and infliximab clearance were investigated as predictors of the relapse hazard risk. The infliximab clearance was calculated using weighted averaging of the estimates of 18 population pharmacokinetics models.1 Results In total, 37% of patients (n=11) remained relapse-free until one year after infliximab interval extension (Figure 1). A time-constant (exponential) hazard model proved best to describe the relapse data of patients with CD (Figure 2, Table 1). The Gompertz hazard model best described the data of patients with UC, with the relapse hazard risk increasing over time. Patients with CD had an overall higher relapse hazard risk than patients with UC. For patients with UC, the infliximab trough concentration was negatively related to the relapse hazard risk and was included in the model using a sigmoidal inhibitory Emax function. Also, in patients with UC, a higher infliximab clearance was associated with an increase in the relapse risk. The infliximab clearance was also a predictor of the relapse hazard risk, but its effect could not be precisely estimated. Conclusion Patients with CD had a higher relapse risk than patients with UC. Only in patients with UC, the hazard risk increased with time, but this risk was lower when the infliximab trough concentration increased. No exposure-response relationship was observed in patients with CD. Results of this exploratory analysis should be interpreted with care and prospective confirmation is awaited (MODIFI study; NCT04982172).2 1Kantasiripitak W. et al. CPT PSP. 2022 2Sheiner LB. et al. CPT. 1997
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ecco-jcc/jjac190.0831
- https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i833/48954766/jjac190.0831.pdf
- OA Status
- bronze
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4318539057
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4318539057Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ecco-jcc/jjac190.0831Digital Object Identifier
- Title
-
P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion intervalWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-01-30Full publication date if available
- Authors
-
Wannee Kantasiripitak, An Outtier, Debby Thomas, João Sabino, Séverine Vermeire, Maria Rosaria Ferrante, Erwin DreesenList of authors in order
- Landing page
-
https://doi.org/10.1093/ecco-jcc/jjac190.0831Publisher landing page
- PDF URL
-
https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i833/48954766/jjac190.0831.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i833/48954766/jjac190.0831.pdfDirect OA link when available
- Concepts
-
Infliximab, Medicine, Hazard ratio, Internal medicine, Ulcerative colitis, Confidence interval, Proportional hazards model, Population, Surgery, Gastroenterology, Disease, Environmental healthTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4318539057 |
|---|---|
| doi | https://doi.org/10.1093/ecco-jcc/jjac190.0831 |
| ids.doi | https://doi.org/10.1093/ecco-jcc/jjac190.0831 |
| ids.openalex | https://openalex.org/W4318539057 |
| fwci | 0.0 |
| type | article |
| title | P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval |
| biblio.issue | Supplement_1 |
| biblio.volume | 17 |
| biblio.last_page | i834 |
| biblio.first_page | i833 |
| topics[0].id | https://openalex.org/T10134 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9990000128746033 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1311 |
| topics[0].subfield.display_name | Genetics |
| topics[0].display_name | Inflammatory Bowel Disease |
| topics[1].id | https://openalex.org/T13569 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9940000176429749 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2713 |
| topics[1].subfield.display_name | Epidemiology |
| topics[1].display_name | Microscopic Colitis |
| topics[2].id | https://openalex.org/T12255 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.984499990940094 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Biosimilars and Bioanalytical Methods |
| is_xpac | False |
| apc_list.value | 3881 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4185 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777138892 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9100497961044312 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q415264 |
| concepts[0].display_name | Infliximab |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.7080034017562866 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C207103383 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6693301796913147 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[2].display_name | Hazard ratio |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5411945581436157 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C2780479503 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5071260929107666 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1477 |
| concepts[4].display_name | Ulcerative colitis |
| concepts[5].id | https://openalex.org/C44249647 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5023069381713867 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[5].display_name | Confidence interval |
| concepts[6].id | https://openalex.org/C50382708 |
| concepts[6].level | 2 |
| concepts[6].score | 0.45185840129852295 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[6].display_name | Proportional hazards model |
| concepts[7].id | https://openalex.org/C2908647359 |
| concepts[7].level | 2 |
| concepts[7].score | 0.42747071385383606 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2625603 |
| concepts[7].display_name | Population |
| concepts[8].id | https://openalex.org/C141071460 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3540439009666443 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[8].display_name | Surgery |
| concepts[9].id | https://openalex.org/C90924648 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3263764977455139 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[9].display_name | Gastroenterology |
| concepts[10].id | https://openalex.org/C2779134260 |
| concepts[10].level | 2 |
| concepts[10].score | 0.18452057242393494 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[10].display_name | Disease |
| concepts[11].id | https://openalex.org/C99454951 |
| concepts[11].level | 1 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q932068 |
| concepts[11].display_name | Environmental health |
| keywords[0].id | https://openalex.org/keywords/infliximab |
| keywords[0].score | 0.9100497961044312 |
| keywords[0].display_name | Infliximab |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.7080034017562866 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/hazard-ratio |
| keywords[2].score | 0.6693301796913147 |
| keywords[2].display_name | Hazard ratio |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.5411945581436157 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/ulcerative-colitis |
| keywords[4].score | 0.5071260929107666 |
| keywords[4].display_name | Ulcerative colitis |
| keywords[5].id | https://openalex.org/keywords/confidence-interval |
| keywords[5].score | 0.5023069381713867 |
| keywords[5].display_name | Confidence interval |
| keywords[6].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[6].score | 0.45185840129852295 |
| keywords[6].display_name | Proportional hazards model |
| keywords[7].id | https://openalex.org/keywords/population |
| keywords[7].score | 0.42747071385383606 |
| keywords[7].display_name | Population |
| keywords[8].id | https://openalex.org/keywords/surgery |
| keywords[8].score | 0.3540439009666443 |
| keywords[8].display_name | Surgery |
| keywords[9].id | https://openalex.org/keywords/gastroenterology |
| keywords[9].score | 0.3263764977455139 |
| keywords[9].display_name | Gastroenterology |
| keywords[10].id | https://openalex.org/keywords/disease |
| keywords[10].score | 0.18452057242393494 |
| keywords[10].display_name | Disease |
| language | en |
| locations[0].id | doi:10.1093/ecco-jcc/jjac190.0831 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735960814 |
| locations[0].source.issn | 1873-9946, 1876-4479 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1873-9946 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Crohn s and Colitis |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | |
| locations[0].pdf_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i833/48954766/jjac190.0831.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Crohn's and Colitis |
| locations[0].landing_page_url | https://doi.org/10.1093/ecco-jcc/jjac190.0831 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5018425502 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-9285-799X |
| authorships[0].author.display_name | Wannee Kantasiripitak |
| authorships[0].countries | BE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[0].affiliations[0].raw_affiliation_string | University of Leuven, Department of Pharmaceutical and Pharmacological Sciences , Leuven, Belgium |
| authorships[0].institutions[0].id | https://openalex.org/I99464096 |
| authorships[0].institutions[0].ror | https://ror.org/05f950310 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | KU Leuven |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | W Kantasiripitak |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | University of Leuven, Department of Pharmaceutical and Pharmacological Sciences , Leuven, Belgium |
| authorships[1].author.id | https://openalex.org/A5061164814 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7351-0023 |
| authorships[1].author.display_name | An Outtier |
| authorships[1].countries | BE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[1].affiliations[0].raw_affiliation_string | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I99464096 |
| authorships[1].affiliations[1].raw_affiliation_string | University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[1].institutions[0].id | https://openalex.org/I99464096 |
| authorships[1].institutions[0].ror | https://ror.org/05f950310 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[1].institutions[0].country_code | BE |
| authorships[1].institutions[0].display_name | KU Leuven |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | A Outtier |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium, University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[2].author.id | https://openalex.org/A5006826596 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-3075-9846 |
| authorships[2].author.display_name | Debby Thomas |
| authorships[2].countries | BE |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[2].affiliations[0].raw_affiliation_string | University of Leuven, Department of Pharmaceutical and Pharmacological Sciences , Leuven, Belgium |
| authorships[2].institutions[0].id | https://openalex.org/I99464096 |
| authorships[2].institutions[0].ror | https://ror.org/05f950310 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[2].institutions[0].country_code | BE |
| authorships[2].institutions[0].display_name | KU Leuven |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | D Thomas |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | University of Leuven, Department of Pharmaceutical and Pharmacological Sciences , Leuven, Belgium |
| authorships[3].author.id | https://openalex.org/A5077041880 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-8892-7075 |
| authorships[3].author.display_name | João Sabino |
| authorships[3].countries | BE |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[3].affiliations[0].raw_affiliation_string | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I99464096 |
| authorships[3].affiliations[1].raw_affiliation_string | University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[3].institutions[0].id | https://openalex.org/I99464096 |
| authorships[3].institutions[0].ror | https://ror.org/05f950310 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[3].institutions[0].country_code | BE |
| authorships[3].institutions[0].display_name | KU Leuven |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | J Sabino |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium, University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[4].author.id | https://openalex.org/A5019474609 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-9942-3019 |
| authorships[4].author.display_name | Séverine Vermeire |
| authorships[4].countries | BE |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[4].affiliations[0].raw_affiliation_string | University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I99464096 |
| authorships[4].affiliations[1].raw_affiliation_string | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium |
| authorships[4].institutions[0].id | https://openalex.org/I99464096 |
| authorships[4].institutions[0].ror | https://ror.org/05f950310 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[4].institutions[0].country_code | BE |
| authorships[4].institutions[0].display_name | KU Leuven |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | S Vermeire |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium, University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[5].author.id | https://openalex.org/A5011273176 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9813-2420 |
| authorships[5].author.display_name | Maria Rosaria Ferrante |
| authorships[5].countries | BE |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[5].affiliations[0].raw_affiliation_string | University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I99464096 |
| authorships[5].affiliations[1].raw_affiliation_string | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium |
| authorships[5].institutions[0].id | https://openalex.org/I99464096 |
| authorships[5].institutions[0].ror | https://ror.org/05f950310 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[5].institutions[0].country_code | BE |
| authorships[5].institutions[0].display_name | KU Leuven |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | M Ferrante |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | University Hospitals Leuven, Department of Gastroenterology and Hepatology , Leuven, Belgium, University of Leuven, Department of Chronic Diseases and Metabolism , Leuven, Belgium |
| authorships[6].author.id | https://openalex.org/A5024846292 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-0785-2930 |
| authorships[6].author.display_name | Erwin Dreesen |
| authorships[6].countries | BE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I99464096 |
| authorships[6].affiliations[0].raw_affiliation_string | University of Leuven, Department of Pharmaceutical and Pharmacological Sciences , Leuven, Belgium |
| authorships[6].institutions[0].id | https://openalex.org/I99464096 |
| authorships[6].institutions[0].ror | https://ror.org/05f950310 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I99464096 |
| authorships[6].institutions[0].country_code | BE |
| authorships[6].institutions[0].display_name | KU Leuven |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | E Dreesen |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | University of Leuven, Department of Pharmaceutical and Pharmacological Sciences , Leuven, Belgium |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i833/48954766/jjac190.0831.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10134 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9990000128746033 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1311 |
| primary_topic.subfield.display_name | Genetics |
| primary_topic.display_name | Inflammatory Bowel Disease |
| related_works | https://openalex.org/W2135637002, https://openalex.org/W4303422230, https://openalex.org/W2039430653, https://openalex.org/W2793335702, https://openalex.org/W2994686985, https://openalex.org/W4210646467, https://openalex.org/W2154948599, https://openalex.org/W2913113213, https://openalex.org/W4254083861, https://openalex.org/W2090763189 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1093/ecco-jcc/jjac190.0831 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735960814 |
| best_oa_location.source.issn | 1873-9946, 1876-4479 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1873-9946 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Journal of Crohn s and Colitis |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i833/48954766/jjac190.0831.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of Crohn's and Colitis |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ecco-jcc/jjac190.0831 |
| primary_location.id | doi:10.1093/ecco-jcc/jjac190.0831 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735960814 |
| primary_location.source.issn | 1873-9946, 1876-4479 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1873-9946 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Crohn s and Colitis |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | |
| primary_location.pdf_url | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i833/48954766/jjac190.0831.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Crohn's and Colitis |
| primary_location.landing_page_url | https://doi.org/10.1093/ecco-jcc/jjac190.0831 |
| publication_date | 2023-01-30 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.A | 178 |
| abstract_inverted_index.a | 63, 103, 255, 265, 283, 303 |
| abstract_inverted_index.13 | 49 |
| abstract_inverted_index.18 | 156 |
| abstract_inverted_index.2, | 195 |
| abstract_inverted_index.30 | 44 |
| abstract_inverted_index.CD | 193, 220, 301 |
| abstract_inverted_index.In | 161 |
| abstract_inverted_index.No | 333 |
| abstract_inverted_index.W. | 361 |
| abstract_inverted_index.We | 29 |
| abstract_inverted_index.an | 25, 222, 272 |
| abstract_inverted_index.as | 137 |
| abstract_inverted_index.at | 96 |
| abstract_inverted_index.be | 295, 348 |
| abstract_inverted_index.et | 362, 369 |
| abstract_inverted_index.in | 10, 70, 251, 261, 274, 312, 338 |
| abstract_inverted_index.is | 355 |
| abstract_inverted_index.of | 34, 109, 118, 139, 152, 155, 164, 190, 206, 285, 343 |
| abstract_inverted_index.or | 89 |
| abstract_inverted_index.to | 31, 185, 243 |
| abstract_inverted_index.(17 | 47 |
| abstract_inverted_index.1). | 177, 197 |
| abstract_inverted_index.37% | 163 |
| abstract_inverted_index.All | 67 |
| abstract_inverted_index.CD, | 48 |
| abstract_inverted_index.CD. | 341 |
| abstract_inverted_index.CPT | 364 |
| abstract_inverted_index.For | 232 |
| abstract_inverted_index.LB. | 368 |
| abstract_inverted_index.The | 144, 198, 278 |
| abstract_inverted_index.UC, | 209, 235, 264, 315 |
| abstract_inverted_index.UC. | 231, 310 |
| abstract_inverted_index.al. | 363, 370 |
| abstract_inverted_index.and | 16, 79, 82, 112, 126, 132, 248, 352 |
| abstract_inverted_index.but | 290, 322 |
| abstract_inverted_index.had | 221, 302 |
| abstract_inverted_index.has | 7 |
| abstract_inverted_index.its | 291 |
| abstract_inverted_index.not | 294 |
| abstract_inverted_index.one | 170 |
| abstract_inverted_index.the | 3, 116, 140, 153, 187, 204, 211, 236, 244, 252, 275, 286, 316, 328 |
| abstract_inverted_index.was | 100, 147, 240, 249, 269, 281, 325, 336 |
| abstract_inverted_index.who | 20, 51 |
| abstract_inverted_index.(CD) | 15 |
| abstract_inverted_index.(UC) | 19 |
| abstract_inverted_index.1997 | 372 |
| abstract_inverted_index.2022 | 366 |
| abstract_inverted_index.CPT. | 371 |
| abstract_inverted_index.Data | 42 |
| abstract_inverted_index.Emax | 258 |
| abstract_inverted_index.Only | 311 |
| abstract_inverted_index.PSP. | 365 |
| abstract_inverted_index.UC), | 50 |
| abstract_inverted_index.[FC] | 92 |
| abstract_inverted_index.[UC] | 78 |
| abstract_inverted_index.also | 282 |
| abstract_inverted_index.been | 8 |
| abstract_inverted_index.best | 184, 202 |
| abstract_inverted_index.care | 351 |
| abstract_inverted_index.data | 189, 205 |
| abstract_inverted_index.from | 43, 62 |
| abstract_inverted_index.loss | 108 |
| abstract_inverted_index.mg/L | 88 |
| abstract_inverted_index.over | 216 |
| abstract_inverted_index.risk | 214, 227, 247, 306, 318, 324 |
| abstract_inverted_index.than | 228, 307 |
| abstract_inverted_index.this | 323, 344 |
| abstract_inverted_index.were | 60, 69, 124, 135 |
| abstract_inverted_index.when | 327 |
| abstract_inverted_index.with | 12, 107, 192, 208, 210, 219, 230, 234, 263, 271, 300, 309, 314, 320, 340, 350 |
| abstract_inverted_index.year | 171 |
| abstract_inverted_index.≤1 | 77 |
| abstract_inverted_index.≤8 | 80 |
| abstract_inverted_index.(TTE) | 105 |
| abstract_inverted_index.Also, | 260 |
| abstract_inverted_index.Table | 196 |
| abstract_inverted_index.[CD]) | 81 |
| abstract_inverted_index.[CRP] | 86 |
| abstract_inverted_index.adult | 45 |
| abstract_inverted_index.after | 37, 172 |
| abstract_inverted_index.aimed | 30 |
| abstract_inverted_index.being | 115 |
| abstract_inverted_index.could | 293 |
| abstract_inverted_index.event | 117 |
| abstract_inverted_index.lower | 326 |
| abstract_inverted_index.model | 106, 182, 201, 253 |
| abstract_inverted_index.risk, | 289 |
| abstract_inverted_index.risk. | 143, 277 |
| abstract_inverted_index.time, | 321 |
| abstract_inverted_index.time. | 217 |
| abstract_inverted_index.type, | 128 |
| abstract_inverted_index.until | 169 |
| abstract_inverted_index.using | 102, 149, 254 |
| abstract_inverted_index.(n=11) | 166 |
| abstract_inverted_index.[PRO2] | 76 |
| abstract_inverted_index.effect | 292 |
| abstract_inverted_index.faecal | 90 |
| abstract_inverted_index.hazard | 122, 142, 181, 200, 213, 226, 246, 288, 317 |
| abstract_inverted_index.higher | 224, 266, 304 |
| abstract_inverted_index.mg/kg) | 94 |
| abstract_inverted_index.proved | 183 |
| abstract_inverted_index.should | 347 |
| abstract_inverted_index.study; | 358 |
| abstract_inverted_index.total, | 162 |
| abstract_inverted_index.trough | 238, 330 |
| abstract_inverted_index.(Figure | 176, 194 |
| abstract_inverted_index.(MODIFI | 357 |
| abstract_inverted_index.Results | 160, 342 |
| abstract_inverted_index.Various | 121 |
| abstract_inverted_index.awaited | 356 |
| abstract_inverted_index.colitis | 18 |
| abstract_inverted_index.disease | 14, 127 |
| abstract_inverted_index.earlier | 26, 57 |
| abstract_inverted_index.outcome | 75 |
| abstract_inverted_index.overall | 223 |
| abstract_inverted_index.protein | 85 |
| abstract_inverted_index.relapse | 141, 188, 212, 225, 245, 276, 287, 305 |
| abstract_inverted_index.related | 242 |
| abstract_inverted_index.search. | 66 |
| abstract_inverted_index.2Sheiner | 367 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Gompertz | 199 |
| abstract_inverted_index.Methods: | 41 |
| abstract_inverted_index.Patients | 218, 299 |
| abstract_inverted_index.analysis | 346 |
| abstract_inverted_index.clinical | 72, 111 |
| abstract_inverted_index.database | 65 |
| abstract_inverted_index.describe | 186 |
| abstract_inverted_index.identify | 32 |
| abstract_inverted_index.included | 250 |
| abstract_inverted_index.increase | 273 |
| abstract_inverted_index.infusion | 5 |
| abstract_inverted_index.interest | 119 |
| abstract_inverted_index.interval | 6, 27, 39, 54, 58, 97, 174 |
| abstract_inverted_index.modelled | 101 |
| abstract_inverted_index.models.1 | 159 |
| abstract_inverted_index.observed | 337 |
| abstract_inverted_index.patients | 11, 46, 68, 165, 191, 207, 229, 233, 262, 308, 313, 339 |
| abstract_inverted_index.remained | 167 |
| abstract_inverted_index.response | 23 |
| abstract_inverted_index.weighted | 150 |
| abstract_inverted_index.&lt;5 | 87 |
| abstract_inverted_index.(two-item | 73 |
| abstract_inverted_index.Crohn’s | 13 |
| abstract_inverted_index.Extending | 2 |
| abstract_inverted_index.attempted | 9 |
| abstract_inverted_index.averaging | 151 |
| abstract_inverted_index.clearance | 134, 146, 268, 280 |
| abstract_inverted_index.collected | 61 |
| abstract_inverted_index.described | 203 |
| abstract_inverted_index.estimates | 154 |
| abstract_inverted_index.explored, | 125 |
| abstract_inverted_index.extension | 55, 175 |
| abstract_inverted_index.following | 24, 56 |
| abstract_inverted_index.function. | 259 |
| abstract_inverted_index.functions | 123 |
| abstract_inverted_index.increased | 319 |
| abstract_inverted_index.precisely | 296 |
| abstract_inverted_index.predictor | 284 |
| abstract_inverted_index.remission | 36, 95, 114 |
| abstract_inverted_index.sigmoidal | 256 |
| abstract_inverted_index.sustained | 21, 35 |
| abstract_inverted_index.treatment | 22 |
| abstract_inverted_index.underwent | 52 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 298 |
| abstract_inverted_index.associated | 270 |
| abstract_inverted_index.biological | 83, 113 |
| abstract_inverted_index.calculated | 148 |
| abstract_inverted_index.estimated. | 297 |
| abstract_inverted_index.extension. | 40, 98 |
| abstract_inverted_index.increased. | 332 |
| abstract_inverted_index.increasing | 215 |
| abstract_inverted_index.infliximab | 4, 38, 53, 130, 133, 145, 173, 237, 267, 279, 329 |
| abstract_inverted_index.inhibitory | 257 |
| abstract_inverted_index.negatively | 241 |
| abstract_inverted_index.population | 157 |
| abstract_inverted_index.predictors | 33, 138 |
| abstract_inverted_index.ulcerative | 17 |
| abstract_inverted_index.&lt;250 | 93 |
| abstract_inverted_index.(C-reactive | 84 |
| abstract_inverted_index.exploratory | 345 |
| abstract_inverted_index.interpreted | 349 |
| abstract_inverted_index.prospective | 353 |
| abstract_inverted_index.shortening, | 59 |
| abstract_inverted_index.shortening. | 28 |
| abstract_inverted_index.(NONMEM7.5). | 120 |
| abstract_inverted_index.calprotectin | 91 |
| abstract_inverted_index.confirmation | 354 |
| abstract_inverted_index.investigated | 136 |
| abstract_inverted_index.relapse-free | 168 |
| abstract_inverted_index.relationship | 335 |
| abstract_inverted_index.steroid-free | 71, 110 |
| abstract_inverted_index.time-varying | 129 |
| abstract_inverted_index.(exponential) | 180 |
| abstract_inverted_index.concentration | 239, 331 |
| abstract_inverted_index.single-centre | 64 |
| abstract_inverted_index.time-constant | 179 |
| abstract_inverted_index.time-to-event | 104 |
| abstract_inverted_index.NCT04982172).2 | 359 |
| abstract_inverted_index.concentrations | 131 |
| abstract_inverted_index.1Kantasiripitak | 360 |
| abstract_inverted_index.Time-to-relapse | 99 |
| abstract_inverted_index.patient-reported | 74 |
| abstract_inverted_index.pharmacokinetics | 158 |
| abstract_inverted_index.exposure-response | 334 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.01016252 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |